Description
Background:
Natalizumab (Tysabri) is a humanized monoclonal antibody against the cell adhesion molecule alpha-4-integrin used in the treatment of multiple sclerosis and Crohns disease. It blocks the adhesion of leukocytes to endothelial cells by blocking the interaction of the 4-integrin subunit of 41 with VCAM-1 and of 47 with mucosal MAdCAM-1. This prevents autoreactive leukocytes from exiting blood vessels and entering target organs to cause inflammation (reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood-brain barrier).
Intended Use:
For Estimation of Natalizumab (TYSABRI) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Natalizumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Natalizumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Natalizumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Natalizumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!